Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $56.36.
KYMR has been the subject of a number of recent research reports. BMO Capital Markets started coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company. BTIG Research initiated coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective for the company. Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday. They issued a “buy” rating and a $52.00 target price on the stock. Finally, Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd.
Get Our Latest Stock Report on Kymera Therapeutics
Insider Buying and Selling at Kymera Therapeutics
Institutional Investors Weigh In On Kymera Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares during the last quarter. State of Wyoming acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at $45,000. GF Fund Management CO. LTD. bought a new position in shares of Kymera Therapeutics in the 4th quarter worth $55,000. KBC Group NV grew its stake in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the period. Finally, Quarry LP bought a new stake in Kymera Therapeutics in the third quarter valued at about $95,000.
Kymera Therapeutics Price Performance
Shares of Kymera Therapeutics stock opened at $34.37 on Friday. Kymera Therapeutics has a 52-week low of $29.07 and a 52-week high of $53.27. The firm has a market capitalization of $2.23 billion, a PE ratio of -14.69 and a beta of 2.22. The company’s fifty day moving average price is $37.43 and its two-hundred day moving average price is $42.76.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Kymera Therapeutics
- Stock Sentiment Analysis: How it Works
- How to Build the Ultimate Everything ETF Portfolio
- The How and Why of Investing in Gold Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Trading Halts Explained
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.